SELLAS Life Sciences Group, Inc 8-K, filed Jun 9, 2022
SELLAS Life Sciences Group, Inc. (SLS)
8-K
2022-06-09
For: 2022-06-08
View Original
Added on
April 08, 2026
About this 8-K
SELLAS Life Sciences Group, Inc filed this 8-K on June 9, 2022, reporting on events of June 8, 2022.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 8, 2022
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| (Address of Principal Executive Offices) (Zip Code) | ||||||||||||||
Registrant’s telephone number, including area code: | ||||||||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
Annual Meeting of Stockholders
On June 8, 2022, the Company held its Annual Meeting of Stockholders (“Annual Meeting”). There were 11,383,855 shares of common stock, or approximately 55.43% of all outstanding shares, present in person or represented by proxy. At the Annual Meeting, the stockholders voted on the following three proposals and cast their votes as described below.
Proposal 1
The Company’s stockholders re-elected each of the following nominees as a Class III director to the Board of Directors of the Company to hold office until the 2025 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified.
| NAME | FOR | WITHHELD | BROKER NON-VOTES | |||||||||||||||||
| Angelos M. Stergiou | 5,020,918 | 857,185 | 5,505,752 | |||||||||||||||||
| John Varian | 4,678,719 | 1,199,384 | 5,505,752 | |||||||||||||||||
Proposal 2
The Company’s stockholders ratified the appointment of Moss Adams LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES | |||||||||||||||||
| 10,499,410 | 765,119 | 119,326 | 0 | |||||||||||||||||
Proposal 3
The Company’s stockholders approved the non-binding, advisory resolution on the executive compensation of the Company’s named executive officers.
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES | |||||||||||||||||
| 4,224,292 | 1,575,977 | 77,834 | 5,505,752 | |||||||||||||||||
No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SELLAS Life Sciences Group, Inc. | ||||||||||||||||||||||||||
| Date: | June 9, 2022 | By: | /s/ Barbara A. Wood | |||||||||||||||||||||||
| Name: | Barbara A. Wood | |||||||||||||||||||||||||
| Title: | Executive Vice President, General Counsel and Corporate Secretary | |||||||||||||||||||||||||